A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients with Advanced Solid Tumours

Trial Identifier: FPI-2068-101
Sponsor: AstraZeneca
Collaborator:
AstraZeneca
Start Date: July 2024
Primary Completion Date: May 2028
Study Completion Date: May 2028
Condition: Cancer - Other; Gastric Cancer; Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CA, AB Edmonton, AB, CA, T6G 1Z2
CA, Nova Scotia Halifax, Nova Scotia, CA, B3H 2Y9
CA, QC Sherbrooke, QC, CA, J1H 5N4
CA, Quebec Montréal, Quebec, CA, H2X 0A9
US, CA Palo Alto, CA, US, 94304
US, CA Santa Monica, CA, US, 90404
US, IL Chicago, IL, US, 60637
US, MA Boston, MA, US, 02215
US, NE Omaha, NE, US, 68130
US, OH Cleveland, OH, US, 44195
US, TX Houston, TX, US, 77030
US, WA Seattle, WA, US, 98109